Singapore markets close in 5 hours 24 minutes

UroGen Pharma Ltd. (0XOD.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
14.58+1.08 (+8.01%)
At close: 02:48PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.08
52-week change 392.39%
S&P500 52-week change 321.08%
52-week high 324.01
52-week low 30.00
50-day moving average 316.10
200-day moving average 314.63

Share statistics

Avg vol (3-month) 3457
Avg vol (10-day) 3126
Shares outstanding 516.1M
Implied shares outstanding 6N/A
Float 824.37M
% held by insiders 111.35%
% held by institutions 170.49%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -123.61%
Operating margin (ttm)-62.09%

Management effectiveness

Return on assets (ttm)-26.09%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)82.71M
Revenue per share (ttm)2.87
Quarterly revenue growth (yoy)30.10%
Gross profit (ttm)N/A
EBITDA -64.73M
Net income avi to common (ttm)-102.24M
Diluted EPS (ttm)-5.05
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)136.97M
Total cash per share (mrq)4.01
Total debt (mrq)100.21M
Total debt/equity (mrq)N/A
Current ratio (mrq)5.42
Book value per share (mrq)-2.01

Cash flow statement

Operating cash flow (ttm)-76.38M
Levered free cash flow (ttm)-34.14M